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10.Prospective studies evaluating persistence to nonvitamin K antagonist oral anticoagulants
in patients with atrial fibrillation are needed to improve our understanding of drug discon-
tinuation. The study objective was to evaluate if and when patients with newly diagnosed
atrial fibrillation stop dabigatran treatment and to report outcomes following discontinua-
tion. Patients prescribed dabigatran in diverse clinical practice settings were consecutively
enrolled and followed for 2 years. Dabigatran persistence over time, reasons for discontin-
uation, and outcomes post discontinuation were assessed. Of 4,859 patients, aged 70.2 §
10.4 years, 55.7% were male. Overall 2-year dabigatran persistence was 70.9% (95% con-
fidence interval [CI] 69.6 to 72.2). Persistence probability was lower in the first 6-month
period (83.7% [82.7 to 84.8]) than in subsequent periods for patients on dabigatran at the
start of each period (6 to 12 months, 92.5% [91.6 to 93.3]; 12 to 18 months, 95.1% [94.3 to
95.8]; 18 to 24 months, 96.3% [95.6 to 96.9]). Of 1,305 patients (26.9%) who discontinued
dabigatran, adverse events were reported as the reason for discontinuation in 457
(35.0%). Standardized stroke incidence rate post discontinuation (per 100 patient-years)
in patients discontinuing without switching to another oral anticoagulant was 1.76 (95%
CI 0.89 to 2.76) and 1.02 (95% CI 0.43 to 1.76) in those who switched, consistent with the
expected benefit of remaining on treatment. Patients persistent with treatment at 1 year
had >90% probability of remaining persistent at 2 years suggesting clinical interventions
to improve persistence should be focused on the early period following treatment initia-
tion. © 2019 The Authors. Published by Elsevier Inc. This is an open access article under
the CC BY-NC-ND license. (http://creativecommons.org/licenses/by-nc-nd/4.0/) (Am J
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1016/j.amjcard.2019.10.047Atrial fibrillation (AF) is well recognized as an important
independent risk factor for stroke.1 Although current guide-
lines recommend long-term oral anticoagulation (OAC) for
stroke prevention in AF patients with at least 1 additional
stroke risk factor,2 high rates of OAC discontinuation haveposed a barrier to achieving optimal outcomes. Discontinua-
tion has been especially noteworthy in the era before
the availability of nonvitamin K antagonist OACs (NOAC)
with 1-year discontinuation rates exceeding 50%3−5; and
investigations examining persistence or adherence have
384 The American Journal of Cardiology (www.ajconline.org)primarily been based on claims databases,6,7 national health
registers,8−11 or commercial databases.12 Although some evi-
dence indicates discontinuation rates may be lower with
NOACs versus vitamin K antagonists,5,7,13 periods of risk
and reasons for NOAC discontinuation remain poorly under-
stood. Reasons for early discontinuation may differ from rea-
sons patients discontinue after more enduring periods of
stable treatment and this information may be informative for
clinicians implementing management strategies to address
the important clinical barrier of treatment persistence. The
objectives of this analysis from a large prospective global reg-
istry of clinical practice settings were to investigate in newly
diagnosed AF patients initiating dabigatran: treatment persis-
tence over 2 years; predictors of discontinuation; reported rea-
sons for discontinuation as a function of time; and stroke,
bleeding, and mortality outcomes following discontinuation.Methods
Analyses were conducted using data from phase 2 of
the GLORIA-AF registry program (registered at https://clin
icaltrials.gov/ct2/home NCT01468701; NCT01671007;
NCT01937377) whereby newly diagnosed AF patients from
various outpatient settings (including hospitals and specialist
and general practice offices) from 44 countries and 5 regions
were prospectively and consecutively enrolled at 982 sites
between 2011 and 2014 (Figure 1). Patients with at least 1
additional stroke risk factor (CHA2DS2-VASc
14 criteria,
including female gender) were eligible for inclusion; patients
with >60 days of previous vitamin K antagonist use wereFigure 1. Distribution of GLORIA-AF patients prescribed dabigatran by re
UK = United Kingdom.excluded. Patients prescribed dabigatran per routine clinical
practice who took at least 1 dose were followed for 2 years,
with the last patient follow-up visits conducted in December
2016. Baseline data only were collected for those prescribed
other anticoagulation therapies in phase 2. Further details on
the GLORIA-AF registry design have been previously pub-
lished,15 and clinical characteristics of all patients enrolled to
phase 2 have been reported.16 Patients provided informed
consent and the study was approved by research ethics
boards where required.
Baseline characteristics, including stroke and bleeding
risk factors used to calculate CHA2DS2-VASc
14 and HAS-
BLED17 scores, as well as AF type (paroxysmal, persistent,
and permanent), AF-related symptom burden based on
the European Heart Rhythm Association classification,18
antithrombotic treatment, medical history, concomitant
medications, and reimbursement status of prescribed OAC,
were collected, and follow-up occurred approximately 3, 6,
12, and 24 months after baseline. Changes to medical con-
ditions, serious adverse events (SAEs), AEs related to any
OAC treatment, and start/stop dates of medications (includ-
ing antithrombotic treatments) were documented. Physi-
cians could choose 1 main reason from a prespecified list
for stopping oral anticoagulation treatment including AEs
or “other reasons.” As physicians could only select 1 rea-
son, they were requested to select the main (and most spe-
cific) reason for discontinuation. If there was >1 reason (eg,
major bleeding, also classified as an SAE), physicians were
requested to select the more specific option—in this case,
the bleeding event.gion. UAE = United Arab Emirates; USA = United States of America;
Arrhythmias & Conduction Disturbances/Dabigatran Persistence and Outcomes in AF 385Baseline data were summarized descriptively, with con-
tinuous variables reported as means (§ standard deviation
[SD]) and categorical variables reported as absolute fre-
quencies and percentages.
To assess persistence, patients were followed from dabiga-
tran initiation until study withdrawal, death, end of study, or
dabigatran discontinuation, whichever came first. Discontinu-
ation was defined as either a switch to another OAC from
dabigatran or stopping dabigatran for ≥30 days (to exclude
temporary treatment interruptions due to medical procedures
[eg, percutaneous coronary intervention]). Dose adjustments
were not considered in determination of discontinuation for
this analysis. Kaplan-Meier time-to-event analyses were used
to calculate probabilities and 95% confidence intervals (CIs)
for dabigatran persistence over 2 years and for 6-month incre-
ments from the time of treatment initiation (for subsets of
patients remaining on treatment at the start of each interval).
Reported reasons for dabigatran discontinuation were
summarized descriptively and grouped into events repre-
senting AEs or SAEs, and other events (Table 1). Reported
reasons for dabigatran discontinuation were described for
4 periods: following treatment initiation (0 to 3 and 3 to
6 months), stabilizing (6 to 12 months), and more enduring
treatment (≥12 months). A sensitivity analysis to evaluate
the potential effect of misclassifying discontinuation due to
AEs/SAEs as “other” reasons was carried out by exploring
whether any AEs/SAEs were reported 14 days before dis-
continuation in this group.
Two Cox regression model approaches were used. To
identify overall predictors of dabigatran discontinuation dur-
ing follow-up, a multivariable Cox regression model, includ-
ing region and patient clinical and sociodemographic
characteristics was used to explore predictors of nonpersis-
tence. Variables included in the model were variables denot-
ing region and patient characteristics such as CHA2DS2-
VASc score, age, hypertension, categorization of AF, previousTable 1
Reported reasons for dabigatran discontinuation over 2 years according to time pe
Variable
0 to 3
(n = 474)
3
(n
All adverse events* 189 (39.9%) 93
Serious adverse events 49 (10.3%) 17
Bleeding 39 (8.2%) 20
Dyspepsia 32 (6.8%) 20
Hypersensitivity to agents 17 (3.6%) 7
Severe concomitant medication interaction 4 (0.8%) 1
Bruising 1 (0.2%) 1
Other adverse events 47 (9.9%) 27
Other reasons 285 (60.1%) 189
Cost of treatment 4 (0.8%) 3
Bridging therapy start 5 (1.1%) 5
Social reason (eg, drug/alcohol abuse) 2 (0.4%) 9
Dementia 1 (0.2%) 2
Other reasons not specified 266 (56.1%) 167
Missing reason for switching 7 (1.5%) 3
Time periods are based on planned visit time (eg, 3 and 6 months). One cate
include 173 patients who died while on dabigatran.
*As physicians could only select 1 reason, they were requested to select the maitransient ischemic attack/stroke, and AF type. Hazard ratios
(HR) and 95% CIs were calculated for these predictors. In
addition, as patient clinical characteristics may not have con-
stant effect on persistence over time, time-dependent effects
of patient clinical characteristics on nonpersistence were eval-
uated with a separate multivariable Cox regression model that
included interactions between covariates and indicator func-
tions of time for the 4 following time intervals: 0 to 3, 3 to 6,
6 to 12, and ≥12 months.
Stroke, major bleeding, vascular, and all-cause death
were assessed from discontinuation until end of study in
those who discontinued without switching and in those who
switched to another OAC within 30 days of discontinuation.
Stroke was defined as an acute onset of a focal neurologic
deficit of presumed vascular origin, lasting for 24 hours or
more, or resulting in death. Major bleeding was defined as
overt bleeding associated with a hemoglobin reduction of at
least 20 g/L or leading to a transfusion of at least 2 units of
blood or packed cells, symptomatic bleeding in a critical
area or organ, or life-threatening or fatal bleeding. Inci-
dence rates following discontinuation were standardized
using averages of the stratum-specific incidence rates
(4 strata using cutoffs for low and moderate HAS-BLED
scores and CHA2DS2-VASc scores ≤3 or >3), weighted by
total patient-years in each. Missing data were handled using
multiple imputation to provide unbiased estimates of miss-
ing values, with added random error to compensate for the
imputed information.19 The imputation model was con-
structed upon 54 baseline patient characteristic variables
including those used in the multivariable analyses (refer to
footnote in Table 2 for information on missing data).
Imputed datasets were analyzed separately, and results
combined to provide estimates under the missing at random
assumption. CIs of standardized incidence rates were con-
structed using the bootstrap method.20 SAS version 9.4
(SAS Institute, Cary, NC) was used for all data analyses.riod
Time (months) after initiation of dabigatran
to 6
= 282)
6 to 12
(n = 290)
12 to 24
(n = 259)
Total
(n = 1305)
(33.0%) 95 (32.8%) 80 (30.9%) 457 (35.0%)
(6.0%) 26 (9.0%) 25 (9.7%) 117 (9.0%)
(7.1%) 14 (4.8%) 15 (5.8%) 88 (6.7%)
(7.1%) 24 (8.3%) 10 (3.9%) 86 (6.6%)
(2.5%) 6 (2.1%) 3 (1.2%) 33 (2.5%)
(0.4%) 2 (0.7%) 1 (0.4%) 8 (0.6%)
(0.4%) 2 (0.7%) 2 (0.8%) 6 (0.5%)
(9.6%) 21 (7.2%) 24 (9.3%) 119 (9.1%)
(67.0%) 195 (67.2%) 179 (69.1%) 848 (65.0%)
(1.1%) 1 (0.3%) 24 (9.3%) 32 (2.5%)
(1.8%) 5 (1.7%) 6 (2.3%) 21 (1.6%)
(3.2%) 4 (1.4%) 1 (0.4%) 16 (1.2%)
(0.7%) 1 (0.3%) 0 (0.0%) 4 (0.3%)
(59.2%) 178 (61.4%) 145 (56.0%) 756 (57.9%)
(1.1%) 6 (2.1%) 3 (1.2%) 19 (1.5%)
gory (reason for discontinuation) could be selected per patient. Does not
n (and most specific) reason for discontinuation.
Table 2
Patient characteristics
Variable Total
(n = 4,859)
Age, mean § standard deviation (y) 70.2 § 10.4
Age ≥75 years 1,784 (36.7%)
Body mass index, mean § standard deviation (kg/m2)* 28.9 § 5.9
Women 2,154 (44.3%)
Prior strokey 765 (15.7%)
Prior myocardial infarctionz 426 (8.8%)
Coronary artery diseasex 928 (19.1%)
Heart failurek 1,168 (24.0%)
Hypertension (history){ 3,768 (77.5%)
Diabetes mellitus 1,104 (22.7%)
CHA2DS2-VASC risk score, mean § standard deviation 3.2 § 1.5
Prior bleeding# 248 (5.1%)
HAS-BLED score, mean § standard deviation** 1.2 § 0.9
Renal impairmentyy 18 (0.4%)
Permanent atrial fibrillation 626 (12.9%)
Persistent/paroxysmal atrial fibrillation 4,233 (87.1%)
Asymptomatic/minimally symptomatic 1,410 (29.0%)
Symptomatic 3,449 (71.0%)
Physician specialtyzz
Cardiology 4,251 (87.5%)
General practitioner/geriatrician 164 (3.4%)
Internist 152 (3.1%)
Neurologist 194 (4.0%)
Other 96 (2.0%)
*Missing: 48 patients.
yMissing: 1 patient.
zUnknown: 1 patient.
xUnknown: 135 patients.
kUnknown: 46 patients.
{Unknown: 9 patients.
# Unknown: 95 patients.
**Unknown: 506 patients.
yyUnknown: 37 patients.
zzMissing: 2 patients.
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A total of 15,308 patients were enrolled from 5 regions,
of whom 4,873 were prescribed dabigatran (Figure 1) and
the majority (n = 4,859; 99.7%) took ≥1 dose (14 patients
who did not take any dose were excluded). The mean num-
ber of patients per site was 15.9 (SD § 18.6) and median
was 10 (interquartile range: 17). Baseline characteristics
and medical history of patients are shown in Table 2.
The overall probability of dabigatran treatment persis-
tence was 77.5% (CI 76.2% to 78.6%) at 1 year and 70.9%
(CI 69.6% to 72.2%) at the end of follow-up (2 years). At
end of follow-up, 1,305 patients (26.9%) stopped dabiga-
tran, with 621 (12.8%) switching to another OAC and 684
(14.1%) not starting another OAC within 30 days. Of those
switching, 260 (41.9%) switched to a vitamin K antagonist,
358 (57.6%) to a factor Xa inhibitor, and 3 (0.5%) to an
antiplatelet drug with bridging therapy.
The evaluation of treatment persistence over time
revealed that over half of the total discontinuations occurred
in the first 6 months (n = 756; 57.9%). The estimated proba-
bility of persistence was lowest in the first 6-month interval
following treatment initiation and was successively higher
for each subsequent 6-month interval for those on treatmentat the start of each respective period (Figure 2). For patients
persistent at 1 year, the estimated probability of continuing
treatment for an additional year was >90% (2-year persis-
tence conditional on 1-year persistence [95.1£ 96.3]).
In the overall multivariable Cox regression analyses to
evaluate predictors of dabigatran persistence, relative to
patients in Europe, patients in North America and Asia had
higher discontinuation, and patients in Latin America and
Africa/Middle East had lower discontinuation (Figure 3).
Patients with symptomatic AF, previous bleeding, and pro-
ton pump inhibitor (PPI) use had higher discontinuation
and those with a higher body mass index (BMI) and previ-
ous stroke or transient ischemic attack had lower discontin-
uation (Figure 3). An increase in BMI of 10 units was
associated with a 15% lower rate of discontinuation (HR
0.85 [95% CI 0.77 to 0.94]).
When evaluating predictors of discontinuation by time
(0 to 3, 3 to 6, 6 to 12, and ≥12 months; Supplementary
Table S1), the effect of symptomatic AF on discontinuation
was observed in earlier periods (0 to 3 or 3 to 6 months),
but less visible in the later period (≥12 months; HR [95%
CI] 1.36 [1.13 to 1.65]; 1.48 [1.15 to 1.89]; 1.07 [0.83 to
1.40], respectively). PPI use was associated with higher risk
for discontinuation in the later period (≥12 months) with
HR (95% CI) 1.54 (1.17 to 2.06); in the earlier period (0 to
3 months), HR was 1.03 (0.82 to 1.29). The effect of private
insurance compared with federal/statutory insurance was
associated with greater discontinuation in the later period
(≥12 months: HR [95% CI] 1.35 [1.00 to 1.82]), but not in
the earlier period (0 to 3 months: 0.98 [0.76 to 1.26]).
Reasons reported for stopping dabigatran over 2 years of
follow-up are presented in Table 1 and were further catego-
rized into primary reasons related to AEs (including SAEs) or
not related to AEs. These reasons for discontinuation reported
to be due to AEs/SAEs were not directly linked to AEs
reported in the system. AEs such as bleeding, bruising, dys-
pepsia, hypersensitivity to agents, or severe interactions with
concomitant medication were reported as the reason for dis-
continuation in approximately a third of cases with the remain-
ing two-thirds being reported as “other reasons” (Table 1).
In the sensitivity analysis examining the extent to which
discontinuation with the primary reason documented as
“other” (n = 756) followed an SAE or AE/adverse drug
reaction within 14 days, 44 (5.8%) had an SAE and 14
(1.9%) an AE/adverse drug reaction in the 14 days before
discontinuation.
Patient death was a censoring point for discontinuation,
and therefore these patients did not have a reason for dis-
continuation (n = 173). Of these patients who died, 135
(78.0%) had an SAE within 14 days and 5 (2.9%) had an
AE. As these were not reported by treating physicians as
due to AEs/SAEs, they were not combined with AE/SAE-
attributed discontinuations.
Standardized incidence rates per 100 patient-years for
stroke, major bleeding, vascular, and all-cause death fol-
lowing discontinuation are presented for patients who per-
manently discontinued with and without switching; higher
stroke and mortality rates were observed in the latter group
(Figure 4). The average follow-up duration was »1.3 years
for different patient groups and different outcomes. For the
full cohort of patients evaluated as part of a separate
Figure 2. Risk of discontinuation is highest in the early period following dabigatran treatment initiation and most reasons for discontinuation are not due to
adverse events. The figure shows probabilities and reasons for dabigatran discontinuation (with or without switching to another oral anticoagulant) over
2 years. *Cumulative incidence of persistence at the end of the time period for patients on treatment at the start of the period are shown as Kaplan-Meier esti-
mates and 95% confidence intervals. y“Other” reasons for discontinuation included cost of treatment, bridging therapy start, social reason (eg, drug/alcohol
abuse), dementia, “other” reasons not specified or reason was missing.
Arrhythmias & Conduction Disturbances/Dabigatran Persistence and Outcomes in AF 387investigation, incidence rates for the period on treatment,
censored at the point of discontinuation (per 100 patient-
years, 95% CI) for stroke, major bleeding, vascular death,
and all-cause death were lower than both groups of patients
who discontinued (0.65 [0.48 to 0.87], 0.97 [0.76 to 1.23],
0.85 [0.65 to 1.09], and 2.48 [2.13 to 2.87] respectively].21Discussion
This prospective study of patients on dabigatran showed
the probability of persistence over 2 years exceeded 70%,
which is higher than previously reported persistence rates
to warfarin3,4 and claims-based estimates of persistence to
NOACs.8,10 Furthermore, it was also shown that the great-
est risk for discontinuation is in the early period following
treatment initiation. There are limited prospective studies
of NOAC persistence, and to our knowledge, this is the first
investigation in clinical practice settings examining discon-
tinuation over long-term follow-up.
Patients in Asia and North America had greater discon-
tinuation than patients in Europe, and patients in Latin
America had less discontinuation. Patients with symptom-
atic AF, previous bleeding, and PPI use had more discontin-
uation and those with higher BMI and previous stroke/
transient ischemic attack had lower discontinuation. These
factors may be related to perceived differences in stroke or
bleeding risk factors, or due to AEs.Patients with certain characteristics may simply be more
prone to discontinue earlier, due to factors such as lifestyle,
low treatment satisfaction, or poor tolerance among others
(ie, patients remaining persistent over time become less sus-
ceptible to discontinue; the concept of “depletion of sus-
ceptibles”22). Closer clinical management in the early
period could be warranted to improve commitment to treat-
ment or to help manage side effects and identification of
characteristics associated with discontinuation could sup-
port targeted interventions in these patients.
Discontinuations attributed to AEs occurred with lower
frequency than discontinuations reported due to other rea-
sons. For patients who remained persistent at 1 year, the
probability of remaining on treatment for an additional year
exceeded 90%, suggesting that this is a period of stable
management where less intensive follow-up may be justi-
fied, at least in terms of mitigating poor persistence. It may
be that once tolerance is established (ie, absence of early
AEs), patients are more likely to continue anticoagulation,
although AEs alone did not account for the majority of rea-
sons for discontinuation.
The reasons for discontinuation are complex. Fewer than
half of all reported reasons for discontinuation were directly
related to AEs. Although specific details are not available
for these “other” reasons for discontinuation reported by
clinicians, they are still informative as they represent dis-
continuations not attributed to bleeding or other AEs that
Figure 3. Forest plot of multivariable predictors of dabigatran treatment persistence. Missing data were imputed using a multiple imputation approach (based
on the eligible population) before the analysis. *Adjusted HRs were estimated from a multivariable Cox model including all variables listed here. AF = atrial
fibrillation; BMI = body mass index; CI = confidence interval; HR = hazard ratio; Ref. = reference; TIA = transient ischemic attack.
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Figure 4. Standardized (by CHA2DS2-VASc and HAS-BLED) incidence rates of outcomes in patients who discontinued dabigatran treatment. In case of
recurrent events after dabigatran discontinuation, the first event was considered. As death is a competing risk for discontinuation, patients who died without
date of discontinuation reported were separately examined. CI = confidence interval; OAC = oral anticoagulant.
Arrhythmias & Conduction Disturbances/Dabigatran Persistence and Outcomes in AF 389would be considered clinically appropriate. This finding has
important implications for practice, as well as future
research. It remains an open question whether these “other”
reasons represent potential opportunities to reduce discon-
tinuations through education or other interventions. These
other reasons could relate to patient or physician prefer-
ence, or perceived higher risk for outcome events that
prompt changes in treatment. These are not likely discontin-
uations prompted through “curative” interventions such as
ablation as earlier data in this cohort (presented at the Euro-
pean Heart Rhythm Association [2017]) reported that
>90% of interventions were conducted with an uninter-
rupted anticoagulation regimen.
The importance of the patient’s perspective for making
decisions around anticoagulant choice has been reported in
other studies,23 and these preferences could also have impli-
cations for treatment persistence or switching to an alternative
OAC. Furthermore, if patients’ knowledge of their AF and
risk for thromboembolic outcomes is limited, perceptionssurrounding treatment necessity may affect their motivation
to continue treatment. Indeed, studies have demonstrated that
many patients have poor knowledge of AF and its treat-
ment.24 There may be an opportunity to improve treatment
persistence through education or patient decision aids with
shared decision-making.
The incidence of postdiscontinuation stroke, vascular, and
all-cause death was higher (albeit with broad 95% CIs) in
patients who discontinued without switching to another
OAC compared with those who switched, and both groups
had higher stroke and mortality outcomes following discon-
tinuation than overall patient outcome rates before discontin-
uation. This finding is consistent with the expected benefit of
remaining on oral anticoagulation and similar to retrospec-
tive studies of dabigatran and rivaroxaban prophylaxis.10
However, it should be noted that the decision not to restart
an anticoagulant after discontinuation of dabigatran could
have been due to patients being moribund, resulting in higher
mortality rates in patients not switching, independent from
390 The American Journal of Cardiology (www.ajconline.org)the effect of discontinuing OAC use. Although outcome
numbers were small, major bleeding rates postdiscontinua-
tion were similar between those discontinuing with or with-
out switching to another OAC.
The use of reported start/stop dates of dabigatran may
provide greater accuracy, compared with claims database
analyses that rely on prescription fill dates. Furthermore,
estimated rates of persistence to NOACs can vary even
between studies focused on the same treatment due to dif-
ferences with respect to patient characteristics, timing of
investigation relative to treatment initiation, retrospective
compared with prospective evaluations, study design, and
definitions of nonpersistence. For example, defining non-
persistence by a treatment gap of 14 days10 could include
temporary discontinuations due to procedures, which has
been shown in 1 study to represent almost a quarter of their
patient population.25 As the risk of nonpersistence appears
to stabilize within a year following treatment initiation,
clinicians may consider this early period most critical for
evaluation and intervention.
There are some limitations of this analysis including the
fact that data were collected as part of an observational reg-
istry, which could modify behavior of both treating physi-
cians and patients based on awareness that data would be
reviewed and monitored (“Hawthorne effect”26). Despite
this, there may be benefits of prospective data collection
compared with retrospective database studies in which risk
of missing or inaccurate information is common. Further-
more, patients who consent to participate in a study may be
more likely to persist with treatment than a general AF pop-
ulation. Notwithstanding this, the diverse selection of clini-
cal practice sites, practitioners, and extensive geographical
representation in this study suggest broad clinical applica-
bility of the results. A further notable limitation is that no
specific information on the “other” reasons for discontinua-
tion was collected and start/stop dates were used as a surro-
gate marker for drug intake. Finally, interpretation of
incidence rates of outcomes after dabigatran discontinua-
tion according to presence or absence of switch to another
OAC is limited by relatively high levels of random error as
evidenced by the wide CIs, and potential for unmeasured
confounding.
In conclusion, this prospective analysis of newly diag-
nosed patients with AF showed overall probability of
2-year persistence in patients taking dabigatran was 70.9%.
The period of greatest risk for discontinuation was in the
first 6 months following treatment initiation, and for those
persistent at 1 year, the probability of remaining on treat-
ment for an additional year was >90%. Thus, closer clinical
management in the early period following treatment initia-
tion could potentially enhance commitment to treatment,
improve management of side effects, and ultimately support
better patient outcomes through improved persistence.Disclosures
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